DECALAB

DecaLAB depot is an injectable anabolic preparation. The pharmacologically active substance is nandrolone. The decanoate ester provides the preparation with a duration of action of approximately 3 weeks after injection. Nandrolone is chemically related to the male hormone.

Compared to testosterone it has a pronounced anabolic activity and a reduced androgenic activity. This has been demonstrated in animal bioassays and clarified through receptor binding studies. The low nandrolone androgenicity has been confirmed in clinical use.

Nandrolone Decanoate has been shown to positively influence calcium metabolism and increase bone mass in osteoporosis. In women with disseminated breast carcinoma, it has been reported to produce objective regressions for several months. Also, Nandrolone has a nitrogen saving action.

This effect on protein metabolism has been demonstrated in metabolic studies and is used therapeutically in conditions where there is a protein shortage, for example in debilitating chronic diseases, after major surgery and severe trauma.

In these conditions nandrolone serves as a supportive adjunct to specific treatments and dietary measures, as well as parenteral nutrition. For the recommended doses androgenic effects (such as virilization) are relatively rare. Nandrolone lacks the alpha-Akil C17 group associated with the development of liver dysfunction and cholestasis.

Nandrolone Decanoate is slowly released from the injection site into the blood with a half-life of 6 days. In serum, the ester is rapidly hydrolyzed to nandrolone with a half-life of one hour or less.

The half-life for the combined process of hydrolysis of nandrolone decanoate and distribution and clearance of nandrolone is 4.3 hours.

Nandrolone is metabolized by the liver.

19-norandrosterone, 19-norethiocholanolone, and 19-norepiandrosterone have been identified as metabolites in urine. It is not known whether these metabolites have any pharmacological action.

To promote protein anabolism.

Osteoporosis

For the palliative treatment of selected cases of disseminated breast carcinoma in women.

As an adjuvant in specific therapeutic and dietary measures in pathological conditions characterized by a negative nitrogen balance.

Remark: To obtain an optimal therapeutic effect, it is necessary to administer adequate amounts of vitamins, minerals and proteins in a high calorie diet.

Adverse reactions and side effects

High doses, long-term treatment and / or too frequent administration can cause:

- Virilization in women who are sensitive such as hoarse voice, acne, hirsutism and increased libido; in prepubertal boys as increased frequency of erections and phallic enlargement and in girls as increased pubic hair and hypertrophy of the clitoris. Hoarseness can be the first symptom of a vowel change that can lead to hoarseness in irreversible occasions.

- Amenorrhea.

- Inhibition of spermatogenesis

- Premature epiphyseal closure

- Fluid retention

The pregnancy. Known or suspected carcinoma of the prostate or carcinoma of the breast in men. This medicine should not be used during pregnancy due to the possibility of masculinization of the fetus. There are no data available on the use of this medicine during lactation to establish a potential harm to the baby or a probable influence on milk production.

PRECAUTIONS AND WARNINGS (regarding effects related to carcinogenesis, mutagenesis, teratogenesis and on fertility)

If interruption signs of virilization develop from treatment should be considered, preferably after consultation with the patient.

Patients with any of these conditions should be monitored: latent or overt heart failure, kidney dysfunction, hypertension, or migraine (or a history of these conditions) as anabolic steroids can include fluid retention.

Incomplete Gowth statural as high dose anabolic steroids can accelerate epiphyseal closure.

Spinal cord metastasis or breast carcinoma. In these patients hypercalcemia can develop spontaneously in both cases, and as a result of anabolic steroid therapy. The latter may be indicative of a positive tumor response to hormonal treatment.

However, hypercalcemia must be primarily treated adequately and then hormone therapy can be resumed once the normal calcium level is restored.

Liver failure

The misuse of anabolic steroids to enhance performance in sport carries serious health risks, so it should be discouraged.

Drug interactions and other types of interactions

Anabolic steroids can improve glucose tolerance and reduce the need for insulin or other antidiabetic medications in diabetic patients.

It must be administered by deep intramuscular route.

Osteoporosis: 50 mg every three weeks

As palliative treatment in selected cases of disseminated breast carcinoma in women: 50 mg every 2-3 weeks.

As an adjunct in specific therapies and dietary measures in pathological conditions characterized by a negative nitrogen balance: 25-50 mg every three weeks.

Overdose or accidental ingestion

The acute toxicity of nandrolone decanoate in animals is very low. There are no reports of acute overdose with nandrolone in humans.

10 ml vial

Store at a temperature below 25 ° C in a dry place.

Keep out of the reach of children.

sale only with prescription.